Literature DB >> 21756827

[Detection and clinical significance of Notch1 methylation in breast cancer and intraductal proliferative breast lesions].

Na Zhang1, Zhen-zhu Sun, Feng Li, Yu-wen Cao, Chun-xia Zhao, Wei-hua Liang, Hua-peng Sun, Hong-an Li, Xin-ge Fu.   

Abstract

OBJECTIVE: To explore the relevance between the promoter methylation status of Notch1 gene and the invasive ductal carcinoma and ductal hyperplastic lesions of the breast.
METHODS: Methylation status of Notch1 gene in human breast invasive ductal carcinoma (IDC, n = 89), ductal carcinoma in situ (DCIS, n = 20), atypical ductal hyperplasia (ADH, n = 11) and usual ductal hyperplasia (UDH, n = 20) were quantitatively evaluated by MALDI-TOF MS. The expression of Notch1 protein was detected by immunohistochemical stain (SP method).
RESULTS: Positive expression rates of Notch1 protein in IDC and DCIS were 91.0% (81/89) and 75.0% (15/20), respectively, which were significantly higher than those of ADH (4/11) and UDH (30.0%, 6/20;P < 0.05). Notch1 protein expression was correlated significantly with lymph node metastasis, pathological grades and TNM stages of IDC. The mean methylation levels of Notch1 gene at CpG_3, CpG_4.5 and CpG_8 significantly decreased in IDC group compared with those of DCIS, ADH and UDH groups (P < 0.0083). In breast carcinomas, the mean methylation rates of Notch1 gene at CpG_4.5, CpG_10.11, and CpG_14.15.16 loci in cases with axillary node metastasis were significantly lower than those without axillary node metastasis (P < 0.05); and the methylation rates at CpG_14.15.16 and CpG_18 loci in stage Iwere lower than that in stage II, further lower than that in stage III (P < 0.05); and that in CpG_1.2, CpG_12.13 loci in grade I (highly-differentiated group) were higher than that in grade II (moderate-differentiated group) and grade III (poorly-differentiated group) (P < 0.05); and the methylation rates at CpG_3, CpG_8 and CpG_14.15.16 loci in ER(+) PR(+) HER2(-) group were lower than that in ER(-) PR(-) HER2(+) group (P < 0.05).
CONCLUSIONS: There is an overall hypomethylation of Notch1 gene in breast invasive ductal carcinomas with corresponding over-expression of Notch1 protein. This inverse correlation show that the alteration of protein expression result from hypomethylation oncogene Notch1, and this change may have important significance in breast tumorigenesis and the development. Specific hypomethylation at CpG_3, CpG_ 4.5 and CpG_8 loci of Notch1 gene may play a role in the pathogenesis of breast carcinoma, suggesting the progression and/or malignant transformation from benign glandular lesions of the breast.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21756827

Source DB:  PubMed          Journal:  Zhonghua Bing Li Xue Za Zhi        ISSN: 0529-5807


  4 in total

1.  Quantitative DNA hypomethylation of ligand Jagged1 and receptor Notch1 signifies occurrence and progression of breast carcinoma.

Authors:  Yuwen Cao; Yixiao Li; Na Zhang; Jianming Hu; Liang Yin; Zemin Pan; Yucong Li; Xiaoming Du; Wenjie Zhang; Feng Li
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

2.  Notch1 single nucleotide polymorphism rs3124591 is associated with the risk of development of invasive ductal breast carcinoma in a Chinese population.

Authors:  Yu-Wen Cao; Guo-Xing Wan; Chun-Xia Zhao; Jian-Ming Hu; Li Li; Wei-Hua Liang; Wen-Qin Li; Yu-Cong Li; Yi-Xiao Li; Xiao-Ming Du; Shi-Ying Yu; Feng Li
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

3.  Quantitative DNA hypomethylation of ligand Jagged1 and receptor Notch1 signifies occurrence and progression of breast carcinoma.

Authors:  Yuwen Cao; Yixiao Li; Na Zhang; Jianming Hu; Liang Yin; Zemin Pan; Yucong Li; Xiaoming Du; Wenjie Zhang; Feng Li
Journal:  Am J Cancer Res       Date:  2015-05-15       Impact factor: 6.166

4.  Expression of Notch1 Correlates with Breast Cancer Progression and Prognosis.

Authors:  Xun Yuan; Mingsheng Zhang; Hua Wu; Hanxiao Xu; Na Han; Qian Chu; Shiying Yu; Yuan Chen; Kongming Wu
Journal:  PLoS One       Date:  2015-06-29       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.